| Literature DB >> 36136536 |
Xuekui Nie1, Qianzi Chen1, Chen Wang1, Wangxiang Huang1, Ren Lai2, Qiumin Lu2, Qiyi He1, Xiaodong Yu1.
Abstract
The venom and transcriptome profile of the captive Chinese cobra (Naja atra) is not characterized  until now. Here, LC-MS/MS and illumine technology were used to unveil the venom and trascriptome of neonates and adults N. atra specimens. In captive Chinese cobra, 98 co-existing transcripts for venom-related proteins was contained. A total of 127 proteins belong to 21 protein families were found in the profile of venom. The main components of snake venom were three finger toxins (3-FTx), snake venom metalloproteinase (SVMP), cysteine-rich secretory protein (CRISP), cobra venom factor (CVF), and phosphodiesterase (PDE). During the ontogenesis of captive Chinese cobra, the rearrangement of snake venom composition occurred and with obscure gender difference. CVF, 3-FTx, PDE, phospholipase A2 (PLA2) in adults were more abundant than neonates, while SVMP and CRISP in the neonates was richer than the adults. Ontogenetic changes in the proteome of Chinese cobra venom reveals different strategies for handling prey. The levels of different types of toxin families were dramatically altered in the wild and captive specimens. Therefore, we speculate that the captive process could reshape the snake venom composition vigorously. The clear comprehension of the composition of Chinese cobra venom facilitates the understanding of the mechanism of snakebite intoxication and guides the preparation and administration of traditional antivenom and next-generation drugs for snakebite.&nbsp.Entities:
Keywords: Captive; Chinese cobra; Ontogeny; Proteomics; Snake venom; Transcriptomics
Mesh:
Substances:
Year: 2022 PMID: 36136536 PMCID: PMC9501182 DOI: 10.3390/toxins14090598
Source DB: PubMed Journal: Toxins (Basel) ISSN: 2072-6651 Impact factor: 5.075
Figure 1The 15% SDS-PAGE of N. atra crude venom (40 μg for each lane) under reducing. Lane 1: marker; Lane 2: neonate males; Lane 3: neonate females; Lane 4: adult males; Lane 5: adult females.
Figure 2The breeding process of captive N. atra (A). Ratio of protein in crude venom (B). Snake body total length (C). Snake body weight (D). ♀: female; ♂: male.Significance analysis was performed by one-way ANOVA, p > 0.05 (ns), p < 0.002 (**).
The list of proteins that were identified from N. atra snake venom by LC-MS/MS.
| Protein Accessions | Description |
|---|---|
| V8N8G0 | Alkaline phosphatase |
| ENSNNAP00000025215.1* | Acetylcholinesterase |
| Q9DF56 | Acidic phospholipase A2 |
| P00598 | Acidic phospholipase A2 1 |
| Q9DF33 | Acidic phospholipase A2 2 |
| ENSNNAP00000015782.1* | Acidic phospholipase A2 2 |
| P60045 | Acidic phospholipase A2 3 |
| Q6T179 | Acidic phospholipase A2 4 |
| Q9I900 | Acidic phospholipase A2 D |
| P25498 | Acidic phospholipase A2 E |
| A4FS04 | Acidic phospholipase A2 natratoxin |
| P86542 | Phospholipase A2 3 |
| P00599 | Basic phospholipase A2 1 |
| P60043 | Basic phospholipase A2 1 |
| V8ND68 | Phospholipase B-like |
| Q7LZI1 | Phospholipase A2 inhibitor 31 kDa subunit |
| ENSNNAP00000008460.1* | PLIalpha-like protein |
| V8NQ76 | Atriopeptidase |
| V8N495 | Carboxypeptidase |
| ENSNNAP00000003269.1* | Carboxypeptidase D |
| I2C090 | Ophiophagus venom factor |
| Q91132 | Cobra venom factor |
| Q91132 | Cobra venom factor |
| ENSNNAP00000021869.1* | Cobra venom factor |
| ENSNNAP00000023282.1* | Cobra venom factor |
| ENSNNAP00000010931.1* | Complement C3 |
| ENSNNAP00000013063.1* | Complement C3 |
| Q01833 | Complement C3 |
| Q90WI6 | C-type lectin BML-1 |
| E3P6P4 | Cystatin |
| P86543 | Cysteine-rich venom protein |
| P84807 | Cysteine-rich venom protein 25-A |
| P84808 | Cysteine-rich venom protein kaouthin-2 |
| Q7T1K6 | Cysteine-rich venom protein natrin-1 |
| Q53B46 | Beta-cardiotoxin CTX15 |
| P60305 | Cytotoxin 1 |
| P86541 | Cytotoxin 10 |
| Q9W6W6 | Cytotoxin 10 |
| ENSNNAP00000013731.1* | Cytotoxin 11 |
| Q98956 | Cytotoxin 1b |
| P85429 | Cytotoxin 1f |
| P01442 | Cytotoxin 2 |
| Q9DGH9 | Cytotoxin 2 |
| P01445 | Cytotoxin 2 |
| P01463 | Cytotoxin 2 |
| O93472 | Cytotoxin 2c |
| P01452 | Cytotoxin 4 |
| O93473 | Cytotoxin 4a |
| O73856 | Cytotoxin 4b |
| P07525 | Cytotoxin 5 |
| P01457 | Cytotoxin 5 |
| P24779 | Cytotoxin 5 |
| P25517 | Cytotoxin 5 |
| P24779 | Cytotoxin 5 |
| Q98965 | Cytotoxin 6 |
| P01465 | Cytotoxin 6 |
| P49122 | Cytotoxin 7 |
| O73859 | Cytotoxin 7 |
| P86540 | Cytotoxin 8 |
| P60311 | Cytotoxin KJC3 |
| P60308 | Cytotoxin SP15c |
| P62377 | Cytotoxin-like basic protein |
| P18328 | Muscarinic toxin 2 |
| P82462 | Muscarinic toxin-like protein 1 |
| P82463 | Muscarinic toxin-like protein 2 |
| P82464 | Muscarinic toxin-like protein 3 |
| Q9PSN6 | Neurotoxin 3 |
| Q9DEQ3 | Neurotoxin homolog NL1 |
| Q9W717 | Neurotoxin-like protein NTL2 |
| P60774 | Short neurotoxin 1 |
| P01427 | Short neurotoxin 1 |
| P14613 | Short neurotoxin 1 |
| P01431 | Short neurotoxin 1 |
| P68418 | Short neurotoxin 1 |
| P01424 | Short neurotoxin 1 |
| P01432 | Short neurotoxin 3 |
| E2IU01 | Long neurotoxin 7 |
| E2ITZ9 | Cobrotoxin-b |
| P85092 | Toxin AdTx1 |
| P29180 | Weak neurotoxin 6 |
| O42256 | Weak neurotoxin 6 |
| Q2VBN2 | Weak neurotoxin WNTX34 |
| P01401 | Weak toxin CM-11 |
| P25679 | Weak toxin CM-9a |
| P85520 | Oxiana weak toxin |
| Q9YGI4 | Probable weak neurotoxin NNAM2 |
| P25669 | Long neurotoxin 2 |
| Q2VBP3 | Long neurotoxin LNTX37 |
| P01391 | Alpha-cobratoxin |
| ENSNNAP00000012975.1* | Cobrotoxin |
| P82849 | Cobrotoxin II |
| P59275 | Cobrotoxin-b |
| D9IX97 | Natriuretic peptide Na-NP |
| V8NF35 | Dipeptidyl peptidase 2 |
| V8P9G9 | Venom dipeptidylpeptidase IV |
| ENSNNAP00000025792.1* | Dipeptidyl peptidase 7 |
| V8P395 | Glutathione peroxidase |
| ENSNNAP00000008637.1* | Hyaluronidase-2-like isoform X1 |
| ENSNNAP00000024830.1* | Insulin like growth factor 1 |
| ENSNNAP00000006918.1* | Insulin like growth factor binding protein 3 |
| V8N7H9 | BPTI/Kunitz domain-containing protein-like isoform X2 |
| P20229 | Kunitz-type serine protease inhibitor |
| ENSNNAP00000023266.1* | Kunitz-type serine protease inhibitor 4-like |
| A8QL51 | L-amino acid oxidase |
| ENSNNAP00000002373.1* | L-amino-acid oxidase |
| A8QL58 | L-amino-acid oxidase |
| V8P5W4 | Putative serine carboxypeptidase CPVL |
| ENSNNAP00000011792.1* | Serpin family E member 2 |
| A0A2I4HXH5 | 5′-nucleotidase |
| V8NYW9 | 5′-nucleotidase |
| A8QL53 | Snake venom serine protease NaSP |
| P86545 | Thrombin-like enzyme TLP |
| V8NCP7 | Vascular endothelial growth factor C |
| P61899 | Venom nerve growth factor |
| Q5YF90 | Venom nerve growth factor 1 |
| A0A2D0TC04 | Venom phosphodiesterase |
| P83234 | Vespryn-21 |
| D3TTC2 | Zinc metalloproteinase-disintegrin-like atragin |
| ENSNNAP00000015130.1* | Zinc metalloproteinase-disintegrin-like atragin |
| D5LMJ3 | Zinc metalloproteinase-disintegrin-like atrase-A |
| ENSNNAP00000015250.1* | Zinc metalloproteinase-disintegrin-like atrase-A |
| ENSNNAP00000015377.1* | Zinc metalloproteinase-disintegrin-like atrase-A |
| D6PXE8 | Zinc metalloproteinase-disintegrin-like atrase-B |
| Q9PVK7 | Zinc metalloproteinase-disintegrin-like cobrin |
| A8QL59 | Zinc metalloproteinase-disintegrin-like NaMP |
| Q10749 | Snake venom metalloproteinase-disintegrin-like mocarhagin |
| P82942 | Hemorrhagic metalloproteinase-disintegrin-like kaouthiagin |
“*” Matched with N. naja snake veonom reference proteome (ftp://ftp.ensembl.org/pub/release-101/fasta/naja_naja/pep/, accessed on 22 January 2021) and the others matched with Uniprot (https://www.uniprot.org/). Accessed on 22 January 2021.
The relative abundance of venom components in N. atra venom and quantification of the relative abundance of venom components using TMT label.
| % Proteome | Neonate Males | Neonate Females | Adult Males | Adult Females |
|---|---|---|---|---|
| PLB | 0.07% | 0.06% | 0.10% | 0.10% |
| HAase | 0.09% | 0.10% | 0.11% | 0.11% |
| DPP-IV | 0.14% | 0.14% | 0.18% | 0.14% |
| VEGF | 0.22% | 0.22% | 0.23% | 0.21% |
| PLI | 0.19% | 0.28% | 0.26% | 0.30% |
| CTL | 0.35% | 0.37% | 0.47% | 0.51% |
| LAAO | 0.38% | 0.32% | 0.24% | 0.27% |
| 5′-NT | 0.43% | 0.39% | 0.40% | 0.45% |
| QC | 0.49% | 0.50% | 0.40% | 0.39% |
| SVSP | 0.50% | 0.50% | 0.26% | 0.27% |
| Acidic PLA2 | 0.53% | 0.52% | 0.94% | 1.3% |
| Basic PLA2 | 0.02% | 0.02% | 0.07% | 0.1% |
| KUN | 0.95% | 0.70% | 0.71% | 0.73% |
| NP | 1.05% | 1.83% | 1.03% | 1.08% |
| VESP | 1.12% | 1.18% | 0.72% | 0.86% |
| AChE | 1.44% | 1.23% | 1.80% | 1.41% |
| NGF | 2.52% | 2.70% | 2.82% | 2.94% |
| PDE | 3.49% | 3.30% | 4.35% | 4.51% |
| CVF | 3.53% | 3.92% | 4.70% | 4.78% |
| SVMP(P-III) | 10.23% | 10.13% | 5.02% | 4.93% |
| CRISP | 11.39% | 9.37% | 7.08% | 6.65% |
| LNX(3-FTx) | 0.10% | 0.09% | 0.13% | 0.14% |
| SNX(3-FTx) | 15.67% | 15.73% | 11.00% | 13.65% |
| WNX(3-FTx) | 5.08% | 6.18% | 5.09% | 5.79% |
| CTX(3-FTx) | 40.00% | 40.22% | 51.77% | 48.63% |
Figure 3The relative differences of N. atra venomic groups. (A) Neonate males versus neonate females. (B) Neonate males versus adult males. (C) Neonate females versus adult females. (D) Adult females versus adult males. The red dots represent the upregulated and green dots present the downregulated proteins. p < 0.05(−log10 p > 1.3), |log2FoldChange| > 1. Abbreviations: 3-FTX, three-finger toxins; CRISP, cysteine-rich secretory protein; SVMP, snake venom metalloproteinase; CVF, cobra venom factor; PDE, phosphodiesterase; NGF, nerve growth factor; AChE, acetylcholinesterase; PLA2, phospholipase A2; NP, natriuretic peptide; VESP, vespryns; KUN, kunitz-type inhibitor; CTL, C-type lectin; 5′-NT, 5′-nucleotidase; QC, glutaminyl-peptide cyclotransferases; PLI, phospholipase A2 inhibitor; SVSP, snake venom serine protease; LAAO, L-amino acid oxidase; VEGF, vascular endothelial growth factor; DPP, dipeptidylpeptidase; HAase, hyaluronidase; PLB, phospholipase B; CTX, cytotoxin; WNX, weak neurotoxin; α-CbTx-I, type I alpha-neurotoxin (short neurotoxin, SNX); MTLP, Muscarinic toxin-like protein; NLP, neurotoxin like protein.
Figure 4N. atra 3-FTx sequence alignment analysis. LNX (long neurotoxin) (A). WNX (weak neurotoxin) (B). SNX (short neurotoxin) (C). CTX (cytotoxin) (D). ID: the ID number of the protein in Uniprot. Online multi-sequence alignment by MAFFT Version 7, parameter default value.
Distribution of the SVMP glycosylation modification sites.
| ID | Distribution of Glycosylation Sites (N-linked Asparagine) | ||
|---|---|---|---|
| Metalloprotease Structural Domains | Disintegrin Structural Domain | Cysteine-Rich Structural Domains | |
| P82942 | 304 | - | - |
| D6PXE8 | 320 | - | 509 |
| D3TTC2 | - | 438 | - |
| Q9PVK7 | - | 438 | - |
| Q10749 | 303 | - | 509 |
| D5LMJ3 | 221, 273, 304 | 438 | 527 |
| A8QL59 | 225, 268, 319 | - | 551 |
- No data available. ID: ID number of the protein in Uniprot.
Figure 5SVMP of N. atra sequence alignment analysis. This was compared online by MAFFT Version 7, parameter default value. ID: the ID number of the protein in Uniprot., *: active site.
Figure 6N. atra PLA2 sequence alignment analysis. This was compared online by MAFFT Version 7, parameter default value. ID: the ID number of the protein in Uniprot.
The list of genes that were obtained from the identification of the N. atra venom gland transcriptome. All the genes co-existed in all the groups (FPKM > 1).
| Gene ID | Gene Chromosome | Gene Coding Protein | Abbreviation |
|---|---|---|---|
| ENSNNAG00000009518 | 3 | Alpha-elapitoxin-Nk2a | α-CbTx(3-FTx) |
| ENSNNAG00000009534 | 3 | Muscarinic toxin-like protein 2 | MTLP-2(3-FTx) |
| ENSNNAG00000011050 | 3 | Muscarinic toxin-like protein 3 homolog | MTLP-3(3-FTx) |
| ENSNNAG00000009404 | 3 | Cytotoxin 3a | CTX(3-FTx) |
| ENSNNAG00000009217 | 3 | Cytotoxin 4N | CTX(3-FTx) |
| ENSNNAG00000011032 | 3 | Cytotoxin 2 | CTX(3-FTx) |
| ENSNNAG00000011010 | 3 | Cytotoxin 5 | CTX(3-FTx) |
| ENSNNAG00000008699 | 3 | Probable weak neurotoxin NNAM1 | WNX(3-FTx) |
| ENSNNAG00000008719 | 3 | Tryptophan-containing weak neurotoxin | WNX(3-FTx) |
| ENSNNAG00000009048 | 3 | Neurotoxin-like protein NTL2 | NTL2(3-FTx) |
| ENSNNAG00000011613 | SOZL01001066.1 | Neurotoxin homolog NL1 | NL1(3-FTx) |
| ENSNNAG00000011709 | SOZL01001066.1 | Cardiotoxin 7 | CTX(3-FTx) |
| ENSNNAG00000008731 | 3 | Cobrotoxin | CBT(3-FTx) |
| ENSNNAG00000007474 | 1 | Snake venom 5′-nucleotidase | 5′ NT |
| ENSNNAG00000007520 | 1 | Snake venom 5′-nucleotidase | 5′ NT |
| novel.2091 | SOZL01000663.1 | 5′-nucleotidase | 5′ NT |
| ENSNNAG00000018750 | 2 | 5′-nucleotidase | 5′ NT |
| ENSNNAG00000016482 | SOZL01001525.1 | Acetylcholinesterase | AchE |
| ENSNNAG00000016482 | SOZL01001525.1 | Acetylcholinesterase | AchE |
| ENSNNAG00000015104 | MIC_6 | Aminopeptidase | AP |
| ENSNNAG00000008828 | 2 | Complement C3 | C3 |
| ENSNNAG00000008657 | 2 | Complement C3 | C3 |
| ENSNNAG00000012844 | SOZL01001814.1 | Cathelicidin-related peptide | CATH |
| ENSNNAG00000014282 | 1 | Cysteine-rich venom protein ophanin | CRISP |
| ENSNNAG00000014151 | 1 | Cysteine-rich venom protein ophanin | CRISP |
| ENSNNAG00000018595 | MIC_4 | Cysteine-rich secretory protein | CRISP |
| ENSNNAG00000000526 | 2 | C-type lectin | CTL |
| ENSNNAG00000018045 | 7 | C-type lectin lectoxin-Thr1 | CTL |
| ENSNNAG00000000430 | 2 | C-type lectin | CTL |
| ENSNNAG00000009410 | 1 | C-type lectin | CTL |
| ENSNNAG00000018053 | 7 | C-type lectin | CTL |
| ENSNNAG00000016651 | MIC_7 | C-type lectin | CTL |
| novel.1968 | MIC_9 | Cystatin (cysteine proteinase inhibitor) | CYS |
| ENSNNAG00000010061 | 2 | Cystatin-B | CYS |
| ENSNNAG00000005504 | MIC_9 | Cystatin | CYS |
| ENSNNAG00000012223 | 3 | Cystatin-2 | CYS |
| novel.1967 | MIC_9 | Cystatin | CYS |
| ENSNNAG00000006541 | 1 | Dipeptidyl peptidase IV | DPP-IV |
| ENSNNAG00000013472 | 2 | Glutathione peroxidase 3 | GPX |
| ENSNNAG00000013545 | 1 | Glutathione peroxidase 2 | GPX |
| ENSNNAG00000013509 | 2 | Glutathione peroxidase 6 | GPX |
| ENSNNAG00000008046 | 2 | Glutathione peroxidase 1 | GPX |
| ENSNNAG00000002583 | 2 | Hyaluronidase | HAase |
| ENSNNAG00000005815 | MIC_2 | Hyaluronidase | HAase |
| ENSNNAG00000018577 | MIC_3 | Kunitz-type serine protease inhibitor | KSPI |
| ENSNNAG00000018577 | MIC_3 | Kunitz-type protease inhibitor | KSPI |
| ENSNNAG00000015199 | 3 | Kunitz-type protease inhibitor | KSPI |
| ENSNNAG00000001233 | 1 | Kunitz-type protease inhibitor | KSPI |
| ENSNNAG00000001705 | 2 | L-amino-acid oxidase | LAAO |
| ENSNNAG00000001808 | 2 | L-amino-acid oxidase | LAAO |
| ENSNNAG00000001642 | 2 | L-amino-acid oxidase | LAAO |
| ENSNNAG00000001705 | 2 | L-amino-acid oxidase | LAAO |
| ENSNNAG00000013519 | MIC_2 | Nerve growth factor | NGF |
| ENSNNAG00000004808 | 3 | Venom nerve growth factor | NGF |
| ENSNNAG00000004800 | 3 | Venom nerve growth factor1 | NGF |
| ENSNNAG00000004808 | 3 | Venom nerve growth factor | NGF |
| ENSNNAG00000006727 | 4 | Natriuretic peptide Na-NP | NP |
| ENSNNAG00000006779 | 4 | Natriuretic peptide Na-NP | NP |
| ENSNNAG00000006809 | 4 | Natriuretic peptide Na-NP | NP |
| ENSNNAG00000006727 | 4 | Natriuretic peptide Na-NP | NP |
| ENSNNAG00000000097 | 1 | Venom phosphodiesterase 1 | PDE |
| ENSNNAG00000013762 | MIC_11 | Group IIE secretory phospholipase A2 | PLA2 |
| ENSNNAG00000003407 | 1 | Phospholipase A2 crotoxin basic subunit | PLA2 |
| ENSNNAG00000010611 | SOZL01000342.1 | Acidic phospholipase A2 | PLA2 |
| ENSNNAG00000003618 | 4 | Phospholipase A2 | PLA2 |
| ENSNNAG00000015696 | 7 | Phospholipase B | PLB |
| novel.1890 | MIC_8 | Phospholipase B | PLB |
| novel.1889 | MIC_8 | Phospholipase B | PLB |
| ENSNNAG00000005694 | 4 | PLIalpha-like protein | PLI |
| ENSNNAG00000003592 | MIC_3 | Phospholipase A2 inhibitor | PLI |
| ENSNNAG00000003672 | MIC_3 | Phospholipase A2 inhibitor | PLI |
| ENSNNAG00000013551 | 2 | Snake venom serine protease NaSP | SVSP |
| ENSNNAG00000015301 | MIC_3 | Snake venom serine protease | SVSP |
| ENSNNAG00000015396 | MIC_3 | Snake venom serine protease | SVSP |
| ENSNNAG00000017712 | 6 | Venom prothrombin activator | VPA |
| ENSNNAG00000017242 | 1 | Vascular endothelial growth factor A | VEGF |
| ENSNNAG00000011309 | MIC_5 | Vascular endothelial growth factor | VEGF |
| ENSNNAG00000008620 | MIC_9 | Vascular endothelial growth factor A | VEGF |
| ENSNNAG00000004103 | MIC_2 | Cysteine-rich with EGF-like domain | CREGF |
| ENSNNAG00000001343 | 2 | Cysteine-rich with EGF-like domain protein | CREGF |
| ENSNNAG00000007968 | 4 | Vascular endothelial growth factor C | VEGF |
| ENSNNAG00000017242 | 1 | Vascular endothelial growth factor A | VEGF |
| ENSNNAG00000013375 | SOZL01001403.1 | Cobra venom factor | CVF |
| ENSNNAG00000008178 | 2 | Cobra venom factor | CVF |
| ENSNNAG00000013375 | SOZL01001403.1 | Cobra venom factor | CVF |
| ENSNNAG00000008178 | 2 | Cobra venom factor | CVF |
| novel.1103 | 3 | Snake toxin and toxin-like protein | STLK |
| novel.1007 | 3 | Snake toxin and toxin-like protein | STLK |
| novel.1104 | 3 | Snake toxin and toxin-like protein | STLK |
| novel.2094 | SOZL01000688.1 | Snake toxin and toxin-like protein | STLK |
| ENSNNAG00000009894 | MIC_1 | Zinc metalloproteinase-disintegrin-like NaMP | SVMP |
| ENSNNAG00000017863 | MIC_8 | Disintegrin and metalloproteinase domain-containing protein 9 | SVMP |
| ENSNNAG00000013917 | 2 | A disintegrin and metalloproteinase with thrombospondin motifs 12 | SVMP |
| ENSNNAG00000011023 | Z | Disintegrin and metalloproteinase domain-containing protein 11 | SVMP |
| ENSNNAG00000010003 | MIC_1 | Zinc metalloproteinase-disintegrin-like atragin | SVMP |
| ENSNNAG00000008597 | MIC_6 | A disintegrin and metalloproteinase with thrombospondin motifs 17 | SVMP |
| ENSNNAG00000005308 | MIC_1 | Disintegrin and metalloproteinase domain-containing protein 9 | SVMP |
| novel.1209 | 4 | Zinc metalloprotease | SVMP |
The relative abundance of venom components of N. atra gland venom transcriptomes. Quantification of relative abundance of venom components by TMT label.
| FPKM% | Neonate Males | Neonate Females | Adult Males | Adult Females |
|---|---|---|---|---|
| PLI | 0.001% | 0.001% | 0.001% | 0.004% |
| C3 | 0.005% | 0.002% | 0.007% | 0.008% |
| CREGF | 0.015% | 0.012% | 0.006% | 0.053% |
| AP | 0.015% | 0.013% | 0.007% | 0.062% |
| DPP-IV | 0.017% | 0.007% | 0.014% | 0.022% |
| VEGF | 0.027% | 0.015% | 0.013% | 0.059% |
| PLB | 0.039% | 0.037% | 0.053% | 0.083% |
| HAase | 0.057% | 0.031% | 0.067% | 0.067% |
| VPA | 0.069% | 0.025% | 0.010% | 0.063% |
| CATH | 0.072% | 0.006% | 0.011% | 0.022% |
| AChE | 0.091% | 0.072% | 0.049% | 0.167% |
| CYS | 0.107% | 0.081% | 0.064% | 0.172% |
| PDE | 0.112% | 0.059% | 0.134% | 0.136% |
| SVSP | 0.168% | 0.124% | 0.145% | 0.210% |
| LAAO | 0.213% | 0.121% | 0.055% | 0.207% |
| KUN | 0.221% | 0.151% | 0.203% | 0.221% |
| CVF | 0.223% | 0.096% | 0.213% | 0.179% |
| CTL | 0.253% | 0.212% | 0.177% | 0.456% |
| 5′-NT | 0.347% | 0.211% | 0.154% | 0.400% |
| CRISP | 0.615% | 0.346% | 0.135% | 0.497% |
| NGF | 0.972% | 0.887% | 1.386% | 1.450% |
| SVMP | 0.985% | 0.515% | 0.078% | 0.653% |
| Basic PLA2 | 1.305% | 1.244% | 3.405% | 1.829% |
| Acidic PLA2 | 0.001% | 0.001% | 0.001% | 0.001% |
| STLK | 1.673% | 2.182% | 1.853% | 3.056% |
| GPX | 2.352% | 1.521% | 1.386% | 2.593% |
| NP | 4.738% | 3.806% | 2.556% | 6.932% |
| LNX(3-FTx) | 0.751% | 2.630% | 1.918% | 7.968% |
| CTX(3-FTx) | 37.825% | 38.359% | 26.955% | 29.696% |
| WNX(3-FTx) | 12.815% | 9.078% | 3.417% | 3.429% |
| SNX(3-FTx) | 33.919% | 38.158% | 55.530% | 39.307% |
Abbreviations: 3-FTx, three-finger toxins; NP, natriuretic peptide; STLK, snake toxin and toxin-like protein; GPX, glutathione peroxidase; PLA2, phospholipase A2; NGF, nerve growth factor; SVMP, snake venom metalloproteinase; CRISP, cysteine-rich secretory protein; CTL, C-type lectin; 5′-NT, 5′-nucleotidase; KUN, kunitz-type inhibitor; SVSP, snake venom serine protease; LAAO, L-amino acid oxidase; CVF, cobra venom factor; CYS, cystatin; AChE, acetylcholinesterase; PDE, phosphodiesterase; PLB, phospholipase B; HAase, hyaluronidase; VPA, venom prothrombin activator; AP, aminopeptidase; CREGF, cysteine-rich with EGF-like domain protein; VEGF, vascular endothelial growth factor; DPP IV, dipeptidylpeptidase IV; CATH, cathelicidin-related peptide; C3, complement C3; PLI, phospholipase A2 inhibitor; CTX, cytotoxin; WNX, weak toxin; SNX, short neurotoxin; LNX, long neurotoxin; MTLP, muscarinic toxin-like protein.
Figure 7The correlation analysis of the proteome and venom gland transcriptome of N. atra venom. Neonate males versus adult males (A); neonate females versus neonate males (B); neonate females versus adult females (C); adult females versus adult males (D). T: transcript; P: protein; FC: fold change; R2: Pearson R squared.
Matched N. atra snake venom proteome and venom gland transcriptome.
| Protein Accessions | Gene | Protein Name |
|---|---|---|
| A0A2D0TC04 | ENSNNAG00000000097 | Venom phosphodiesterase |
| A8QL53 | ENSNNAG 00000013551 | Snake venom serine protease NaSP |
| ENSNNAG00000015396 | Snake venom serine protease NaSP | |
| A8QL58 | ENSNNAG00000001808 | L-amino-acid oxidase |
| A8QL59 | ENSNNAG00000009894 | Zinc metalloproteinase-disintegrin |
| ENSNNAG00000008597 | Zinc metalloproteinase-disintegrin | |
| D5LMJ3 | ENSNNAG00000005308 | Zinc metalloproteinase-disintegrin |
| ENSNNAG00000013917 | Zinc metalloproteinase-disintegrin | |
| D9IX97 | ENSNNAG00000006809 | Natriuretic peptide Na-NP |
| ENSNNAG00000006727 | Natriuretic peptide Na-NP | |
| ENSNNAG00000006779 | Natriuretic peptide Na-NP | |
| E3P6P4 | ENSNNAG00000005504 | Cystatin |
| ENSNNAP00000002373.1 | ENSNNAG00000001642 | L-amino-acid oxidase |
| ENSNNAG00000001705 | L-amino-acid oxidase | |
| ENSNNAP00000008460.1 | ENSNNAG00000005694 | PLI alpha-like protein |
| ENSNNAP00000008637.1 | ENSNNAG00000005815 | Hyaluronidase-2-like isoform X1 |
| ENSNNAG00000002583 | Hyaluronidase-2-like isoform X1 | |
| ENSNNAP00000009791.1 | ENSNNAG00000006541 | Venom dipeptidylpeptidase IV |
| ENSNNAP00000011851.1 | ENSNNAG00000008620 | Vascular endothelial growth factor C |
| ENSNNAG00000007968 | Vascular endothelial growth factor C | |
| ENSNNAG00000017242 | Vascular endothelial growth factor C | |
| ENSNNAP00000012520.1 | ENSNNAG00000008178 | Cobra venom factor |
| ENSNNAP00000012975.1 | ENSNNAG00000008731 | Cobrotoxin |
| ENSNNAP00000013063.1 | ENSNNAG00000008657 | Complement C3 |
| ENSNNAP00000014120.1 | ENSNNAG00000009518 | Alpha-cobratoxin |
| ENSNNAP00000015130.1 | ENSNNAG00000010003 | Zinc metalloproteinase-disintegrin |
| ENSNNAP00000021869.1 | ENSNNAG00000013375 | Cobra venom factor |
| ENSNNAP00000023044.1 | ENSNNAG00000001233 | BPTI/Kunitz domain-containing |
| ENSNNAG00000015199 | BPTI/Kunitz domain-containing | |
| ENSNNAP00000025215.1 | ENSNNAG00000016482 | Acetylcholinesterase |
| P00598 | ENSNNAG00000010611 | Acidic phospholipase A2 1 |
| P01442 | ENSNNAG00000009217 | Cytotoxin 2 |
| ENSNNAG00000011010 | Cytotoxin 2 | |
| P01445 | ENSNNAG00000011032 | Cytotoxin 2 |
| P29180 | ENSNNAG00000008699 | Weak neurotoxin 6 |
| P61899 | ENSNNAG00000004808 | Venom nerve growth factor |
| P62377 | ENSNNAG00000011709 | Cytotoxin-like basic protein |
| P86540 | ENSNNAG00000009404 | Cytotoxin 8 |
| Q01833 | ENSNNAG00000008828 | Complement C3 |
| Q10749 | ENSNNAG00000017863 | Snake venom metalloproteinase |
| ENSNNAG00000011023 | Snake venom metalloproteinase | |
| Q5YF90 | ENSNNAG00000004800 | Venom nerve growth factor 1 |
| ENSNNAG00000013519 | Venom nerve growth factor 1 | |
| Q6T179 | ENSNNAG00000013762 | Acidic phospholipase A2 4 |
| ENSNNAG00000003407 | Acidic phospholipase A2 4 | |
| Q7LZI1 | ENSNNAG00000003592 | Phospholipase A2 inhibitor 31 |
| Q7T1K6 | ENSNNAG00000014151 | Cysteine-rich venom protein natrin-1 |
| Q9DEQ3 | ENSNNAG00000011613 | Neurotoxin homolog NL1 |
| ENSNNAG00000011050 | Neurotoxin homolog NL1 | |
| Q9W717 | ENSNNAG00000009048 | Neurotoxin-like protein NTL2 |
| Q9YGI4 | ENSNNAG00000008719 | Probable weak neurotoxin NNAM2 |
| V8P395 | ENSNNAG00000013472 | Glutathione peroxidase |
| ENSNNAG00000008046 | Glutathione peroxidase | |
| ENSNNAG00000013545 | Glutathione peroxidase |
Figure 8The enzyme activities of N. atra crude venom. SVMP (A); LAAO (B); PLA2 (C); 5′-NT (D); AChE (E); LD50 (F). ♀: female; ♂: male. Significance analyzed by Tukey’s multiple comparison test, the value of p > 0.05 (ns), p < 0.05 (*), p < 0.002 (**), p < 0.001 (***).
Figure 9The correlation of N. atra venom protein ratios with corresponding enzyme activities. SVMP (A). LAAO (B). PLA2 (C). 5′-NT (D). AChE (E). LD50 (F). 1: neonate males; 2: neonate females; 3: adult males; 4: adult females. Significance analyzed by Simple linear regression analysis, the value of p < 0.05 considered significant.